156 related articles for article (PubMed ID: 32306475)
1. SFPQ-ABL1-positive B-cell precursor acute lymphoblastic leukemias.
Biloglav A; Olsson-Arvidsson L; Theander J; Behrendtz M; Castor A; Johansson B
Genes Chromosomes Cancer; 2020 Sep; 59(9):540-543. PubMed ID: 32306475
[TBL] [Abstract][Full Text] [Related]
2. t(1;9)(p34;q34)/SFPQ-ABL1 Fusion in a Patient with Ph-Like Common B-Cell Acute Lymphoblastic Leukemia.
Sheng G; Zeng Z; Pan J; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Acta Haematol; 2017; 137(1):40-43. PubMed ID: 27894117
[No Abstract] [Full Text] [Related]
3. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
[TBL] [Abstract][Full Text] [Related]
4. The t(1;9)(p34;q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias.
Duhoux FP; Auger N; De Wilde S; Wittnebel S; Ameye G; Bahloula K; Van den Berg C; Libouton JM; Saussoy P; Grand FH; Demoulin JB; Poirel HA
Leuk Res; 2011 Jul; 35(7):e114-7. PubMed ID: 21388681
[No Abstract] [Full Text] [Related]
5. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
Boer JM; den Boer ML
Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.
Tran TH; Harris MH; Nguyen JV; Blonquist TM; Stevenson KE; Stonerock E; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJG; Reshmi SC; Neuberg DS; Sallan SE; Loh ML; Silverman LB
Blood Adv; 2018 Mar; 2(5):529-533. PubMed ID: 29507076
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
[TBL] [Abstract][Full Text] [Related]
9. Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan.
Imamura T; Kiyokawa N; Kato M; Imai C; Okamoto Y; Yano M; Ohki K; Yamashita Y; Kodama Y; Saito A; Mori M; Ishimaru S; Deguchi T; Hashii Y; Shimomura Y; Hori T; Kato K; Goto H; Ogawa C; Koh K; Taki T; Manabe A; Sato A; Kikuta A; Adachi S; Horibe K; Ohara A; Watanabe A; Kawano Y; Ishii E; Shimada H
Blood Cancer J; 2016 May; 6(5):e419. PubMed ID: 27176795
[TBL] [Abstract][Full Text] [Related]
10. Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.
Hu T; Ciccarelli BT
Leuk Res; 2014 Dec; 38(12):1399-400. PubMed ID: 25449686
[No Abstract] [Full Text] [Related]
11. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.
van der Veer A; Zaliova M; Mottadelli F; De Lorenzo P; Te Kronnie G; Harrison CJ; Cavé H; Trka J; Saha V; Schrappe M; Pieters R; Biondi A; Valsecchi MG; Stanulla M; den Boer ML; Cazzaniga G
Blood; 2014 Mar; 123(11):1691-8. PubMed ID: 24366361
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.
Tanasi I; Ba I; Sirvent N; Braun T; Cuccuini W; Ballerini P; Duployez N; Tanguy-Schmidt A; Tamburini J; Maury S; Doré E; Himberlin C; Duclos C; Chevallier P; Rousselot P; Bonifacio M; Cavé H; Baruchel A; Dombret H; Soulier J; Landman-Parker J; Boissel N; Clappier E
Blood; 2019 Oct; 134(16):1351-1355. PubMed ID: 31434701
[No Abstract] [Full Text] [Related]
13. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
14. ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
Uemura S; Nishimura N; Hasegawa D; Shono A; Sakaguchi K; Matsumoto H; Nakamachi Y; Saegusa J; Yokoi T; Tahara T; Tamura A; Yamamoto N; Saito A; Kozaki A; Kishimoto K; Ishida T; Nino N; Takafuji S; Mori T; Iijima K; Kosaka Y
Int J Hematol; 2018 May; 107(5):604-609. PubMed ID: 29177615
[TBL] [Abstract][Full Text] [Related]
15. Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia.
Ernst T; Score J; Deininger M; Hidalgo-Curtis C; Lackie P; Ershler WB; Goldman JM; Cross NC; Grand F
Br J Haematol; 2011 Apr; 153(1):43-6. PubMed ID: 21391972
[TBL] [Abstract][Full Text] [Related]
16. SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia.
Brown LM; Hediyeh-Zadeh S; Sadras T; Huckstep H; Sandow JJ; Bartolo RC; Kosasih HJ; Davidson NM; Schmidt B; Bjelosevic S; Johnstone R; Webb AI; Khaw SL; Oshlack A; Davis MJ; Ekert PG
Blood Adv; 2022 Apr; 6(7):2373-2387. PubMed ID: 35061886
[TBL] [Abstract][Full Text] [Related]
17. Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis.
Chiaretti S; Tavolaro S; Ghia EM; Ariola C; Matteucci C; Elia L; Maggio R; Messina M; Ricciardi MR; Vitale A; Ritz J; Mecucci C; Guarini A; Foà R
Haematologica; 2007 May; 92(5):619-26. PubMed ID: 17488685
[TBL] [Abstract][Full Text] [Related]
18. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
De Keersmaecker K; Graux C; Odero MD; Mentens N; Somers R; Maertens J; Wlodarska I; Vandenberghe P; Hagemeijer A; Marynen P; Cools J
Blood; 2005 Jun; 105(12):4849-52. PubMed ID: 15713800
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
DeBoer R; Koval G; Mulkey F; Wetzler M; Devine S; Marcucci G; Stone RM; Larson RA; Bloomfield CD; Geyer S; Mullighan CG; Stock W
Leuk Lymphoma; 2016 Oct; 57(10):2298-306. PubMed ID: 26892479
[TBL] [Abstract][Full Text] [Related]
20. ABL1 rearrangements in T-cell acute lymphoblastic leukemia.
Hagemeijer A; Graux C
Genes Chromosomes Cancer; 2010 Apr; 49(4):299-308. PubMed ID: 20073070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
